분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2013-10-11 21:58:04 , Hit : 2155
 J&J's Janssen Buys Rights to Hepatitis C Compound from GSK

GENNewsHighlightsMore » Oct 8, 2013 (Page 1 of 1)
Johnson & Johnson’s Janssen Pharmaceuticals unit said today it acquired GSK2336805, an investigational once-daily NS5a replication complex inhibitor for chronic hepatitis C, from an affiliate of GlaxoSmithKline (GSK).  The price was not disclosed.

Janssen said it acquired from GSK all rights to develop and commercialize GSK2336805, including GSK2336805 used in combination with other drugs.

"This addition will broaden our clinical development program as we continue to look for new investigational interferon-free treatment combinations to combat the hepatitis C virus," Gaston Picchio, hepatitis disease area leader with Janssen, said in a statement. "We're excited to add GSK2336805 to our existing portfolio of direct-acting antivirals (DAAs).”

He said Janssen is dedicated to working with the hepatitis C community to investigate its DAA portfolio in "numerous treatment combinations and patient populations."

Janssen said it plans to launch Phase II studies evaluating GSK2336805 in interferon-free combinations with the investigational protease inhibitor simeprevir (TMC435) and TMC647055, Janssen's once-daily, non-nucleoside polymerase inhibitor, for chronic hepatitis C in adults with compensated liver disease.

Simeprevir is an investigational NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir for genotype 1 and genotype 4 chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis.

Janssen is responsible for the global clinical development of simeprevir and has acquired exclusive near-worldwide marketing rights to the drug candidate, except in Nordic countries, where Medivir retains those rights. Simeprevir was approved in Japan last month and has been submitted for regulatory approval in the United States, Canada, and Europe.

Simeprevir remains in Phase II studies  in combination with several DAAs, with and without ribavirin, as part of interferon-free regimens, Janssen said.







787   Un-junking junk DNA  이성욱 2013/11/15 1875
786   간염 발병시 면역계가 간 손상을 유발하는 기전  이성욱 2013/11/12 2062
785   젊음의 샘 유전자가 성체의 조직 손상을 치유  이성욱 2013/11/11 1944
784   CRISPR Madness  이성욱 2013/11/10 2204
783   RNA Controls Splicing During Gene Expression, Further Evidence of 'RNA World' Origin in Modern Life  이성욱 2013/11/07 2351
782   Experimental Hepatitis C Drug Shows Promise for Preventing Recurrence in Liver Transplant Patients  이성욱 2013/11/06 2170
781   Scientists revolutionize the creation of genetically altered mice to model human disease  이성욱 2013/10/30 2577
780   유방암 발병 위험을 둘러싼 뜨거운 논란: BRCA vs BROCA  이성욱 2013/10/30 2375
779   거세 저항성 전립선 종양을 증식시키는 논코딩  이성욱 2013/08/23 2708
778   First Interferon-Free HCV Regimen Gets Unanimously Positive Vote  이성욱 2013/10/28 2273
777   암 전이와 싸우는 작은 조각의 유전 물질-마이크로 알앤에이  이성욱 2013/10/21 2218
776   감염위험을 증가시키는 HIV 백신  이성욱 2013/10/21 2229
775   형광성 항생제를 이용한 감염지점 파악방법  이성욱 2013/10/17 2110
774   대한민국 간암·간경화 원인은 70%가 B형, 15%가 C형 간염  이성욱 2013/10/14 2853
773   암 게놈 아틀라스 프로젝트- 치명적인 뇌종양의 비밀을 밝히다!!  이성욱 2013/10/14 2289
772   이제 미리 초기 간암 전구세포 확인  이성욱 2013/10/14 2349
771   포유류의 선천성 항 바이러스 파워 발견  이성욱 2013/10/14 2272
  J&J's Janssen Buys Rights to Hepatitis C Compound from GSK  이성욱 2013/10/11 2155
769   제약업계 새 먹거리 ‘바이오베터’…미래 시장 두고 바이오시밀러와 한판  이성욱 2013/10/09 2873
768    3 Win Joint Nobel Prize in Medicine  이성욱 2013/10/08 2325

[이전 10개] [1]..[21][22][23][24] 25 [26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2023 Zeroboard / skin by ROBIN